SrasV1, PubMed, Curation, bibRecord, 002D65

[Targets and studies on anti-SARS drugs].

Identifieur interne : 002D65 ( PubMed/Curation ); précédent : 002D64; suivant : 002D66

[Targets and studies on anti-SARS drugs].

Auteurs : Guan-Hua Du [République populaire de Chine] ; Wei Wang ; Ke-Di Cheng ; Li-Li Cao ; Xiu-Ying Yang ; Ping Zhu

Source :

Yao xue xue bao = Acta pharmaceutica Sinica [ 0513-4870 ] ; 2004.

RBID : pubmed:15171664

Descripteurs français

KwdFr :
- Adjuvants immunologiques (usage thérapeutique), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Conception de médicament, Humains, Médicaments issus de plantes chinoises (usage thérapeutique), Syndrome respiratoire aigu sévère (rééducation et réadaptation), Syndrome respiratoire aigu sévère (traitement médicamenteux), Virus du SRAS ().
MESH :
- pharmacologie : Antiviraux.
- rééducation et réadaptation : Syndrome respiratoire aigu sévère.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- usage thérapeutique : Adjuvants immunologiques, Antiviraux, Médicaments issus de plantes chinoises.
- Animaux, Conception de médicament, Humains, Virus du SRAS.

English descriptors

KwdEn :
- Adjuvants, Immunologic (therapeutic use), Animals, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Drug Design, Drugs, Chinese Herbal (therapeutic use), Humans, SARS Virus (chemistry), SARS Virus (drug effects), Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (rehabilitation).
MESH :
- chemical , pharmacology : Antiviral Agents.
- chemical , therapeutic use : Adjuvants, Immunologic, Antiviral Agents, Drugs, Chinese Herbal.
- chemistry : SARS Virus.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- rehabilitation : Severe Acute Respiratory Syndrome.
- Animals, Drug Design, Humans.

PubMed: 15171664

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002D65

Links to Exploration step

pubmed:15171664

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Targets and studies on anti-SARS drugs].</title>
<author><name sortKey="Du, Guan Hua" sort="Du, Guan Hua" uniqKey="Du G" first="Guan-Hua" last="Du">Guan-Hua Du</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China. dugh@imm.ac.cn</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
</author>
<author><name sortKey="Cheng, Ke Di" sort="Cheng, Ke Di" uniqKey="Cheng K" first="Ke-Di" last="Cheng">Ke-Di Cheng</name>
</author>
<author><name sortKey="Cao, Li Li" sort="Cao, Li Li" uniqKey="Cao L" first="Li-Li" last="Cao">Li-Li Cao</name>
</author>
<author><name sortKey="Yang, Xiu Ying" sort="Yang, Xiu Ying" uniqKey="Yang X" first="Xiu-Ying" last="Yang">Xiu-Ying Yang</name>
</author>
<author><name sortKey="Zhu, Ping" sort="Zhu, Ping" uniqKey="Zhu P" first="Ping" last="Zhu">Ping Zhu</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15171664</idno>
<idno type="pmid">15171664</idno>
<idno type="wicri:Area/PubMed/Corpus">002D65</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D65</idno>
<idno type="wicri:Area/PubMed/Curation">002D65</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D65</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">[Targets and studies on anti-SARS drugs].</title>
<author><name sortKey="Du, Guan Hua" sort="Du, Guan Hua" uniqKey="Du G" first="Guan-Hua" last="Du">Guan-Hua Du</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China. dugh@imm.ac.cn</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wang, Wei" sort="Wang, Wei" uniqKey="Wang W" first="Wei" last="Wang">Wei Wang</name>
</author>
<author><name sortKey="Cheng, Ke Di" sort="Cheng, Ke Di" uniqKey="Cheng K" first="Ke-Di" last="Cheng">Ke-Di Cheng</name>
</author>
<author><name sortKey="Cao, Li Li" sort="Cao, Li Li" uniqKey="Cao L" first="Li-Li" last="Cao">Li-Li Cao</name>
</author>
<author><name sortKey="Yang, Xiu Ying" sort="Yang, Xiu Ying" uniqKey="Yang X" first="Xiu-Ying" last="Yang">Xiu-Ying Yang</name>
</author>
<author><name sortKey="Zhu, Ping" sort="Zhu, Ping" uniqKey="Zhu P" first="Ping" last="Zhu">Ping Zhu</name>
</author>
</analytic>
<series><title level="j">Yao xue xue bao = Acta pharmaceutica Sinica</title>
<idno type="ISSN">0513-4870</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (therapeutic use)</term>
<term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Drug Design</term>
<term>Drugs, Chinese Herbal (therapeutic use)</term>
<term>Humans</term>
<term>SARS Virus (chemistry)</term>
<term>SARS Virus (drug effects)</term>
<term>Severe Acute Respiratory Syndrome (drug therapy)</term>
<term>Severe Acute Respiratory Syndrome (rehabilitation)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (usage thérapeutique)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Médicaments issus de plantes chinoises (usage thérapeutique)</term>
<term>Syndrome respiratoire aigu sévère (rééducation et réadaptation)</term>
<term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term>
<term>Virus du SRAS ()</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Antiviral Agents</term>
<term>Drugs, Chinese Herbal</term>
</keywords>
<keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="rehabilitation" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="rééducation et réadaptation" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Antiviraux</term>
<term>Médicaments issus de plantes chinoises</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Drug Design</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15171664</PMID>
<DateCompleted><Year>2004</Year>
<Month>08</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2006</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0513-4870</ISSN>
<JournalIssue CitedMedium="Print"><Volume>39</Volume>
<Issue>3</Issue>
<PubDate><Year>2004</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Yao xue xue bao = Acta pharmaceutica Sinica</Title>
<ISOAbbreviation>Yao Xue Xue Bao</ISOAbbreviation>
</Journal>
<ArticleTitle>[Targets and studies on anti-SARS drugs].</ArticleTitle>
<Pagination><MedlinePgn>236-40</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Du</LastName>
<ForeName>Guan-hua</ForeName>
<Initials>GH</Initials>
<AffiliationInfo><Affiliation>Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, China. dugh@imm.ac.cn</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Wei</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cheng</LastName>
<ForeName>Ke-di</ForeName>
<Initials>KD</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cao</LastName>
<ForeName>Li-li</ForeName>
<Initials>LL</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Xiu-ying</ForeName>
<Initials>XY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Ping</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>chi</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>China</Country>
<MedlineTA>Yao Xue Xue Bao</MedlineTA>
<NlmUniqueID>21710340R</NlmUniqueID>
<ISSNLinking>0513-4870</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>13</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>8</Month>
<Day>18</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>6</Month>
<Day>3</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15171664</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D65 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002D65 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:15171664
   |texte=   [Targets and studies on anti-SARS drugs].
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:15171664" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

[Targets and studies on anti-SARS drugs].

[Targets and studies on anti-SARS drugs].

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki